Drug reference
omacetaxine
protein translation inhibitor · Antineoplastic agent
protein translation inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
D
FDA category + note
Mechanism
Omacetaxine inhibits protein translation by preventing the initial elongation step of protein synthesis, thereby depleting the cell of short-lived proteins.
Indications
CML with resistance or intolerance to two or more kinase inhibitors
Pharmacokinetics
Half-life
14.6 h (elimination)
Metabolism
hydrolyzed by plasma esterases
Side effects
Common
nauseafatigueinfections
Serious
- myelosuppression
- bleeding
- fetal toxicity
Pregnancy & lactation
Pregnancy
D
Related guidelines
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Heart failure in diabetes
RSSDI · Cardiology · 2023
Drug-resistant tuberculosis
RNTCP · Pulmonology · 2025
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Hypertension in adults
ICMR · Cardiology · 2019
Ask House about omacetaxine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team